Khalid Shah

Professor/Vice Chair of Research, Neurosurgery/Director, Center for Stem Cell & Translational Immunotherapy at Brigham and Women's Hospital/Harvard Medical School Principal Faculty/Harvard Stem Cell Institute, USA

Speaker

Dr. Shah and his team have pioneered major developments in translational cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic cells for cancer. These studies have been published in a number of very high impact journals. Previously, Dr. Shah's translational stem cell work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Recently, Dr. Shah’s laboratory has reverse engineered cancer cells using CRISPR/Cas9 technology and utilized them as therapeutics to treat cancer. This work was published in journal Science Translation Medicine and highlighted world-wide including features on Scientific American, New York Times and Scientific American. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of Cellular therapy and Oncology. In an effort to translate the exciting therapies develped in his laboratory into clinics, he has founded two biotech companies whose main objective is the clinical translation of Cellular Therapies in cancer patients.